Skip to content
Home/Companies/Biotech/AELIX Therapeutics
AELIX Therapeutics

AELIX Therapeutics

Biotech·ES·Active·10yr hold
Entry
2016
Hold
10yr
Status
Active

Who owns AELIX Therapeutics?

AELIX Therapeutics is currently owned by Ysios Capital Partners through Ysios BioFund II Innvierte (2016 vintage), since 2016.

Hand-verified · updated 2026-08-03

Ysios Capital Partners
Investor
Ysios Capital Partners
Ysios BioFund II Innvierte · 2016 · Life Sciences VC

Key facts

HQES
SectorBiotech
StatusActive
Websitewww.aelixtherapeutics.com

More from Ysios BioFund II Innvierte

Other portfolio companies in the same fund.

Anaconda Biomed
Anaconda Biomed
Active
MedTechES· 2017
Babyscripts
Babyscripts
Active
HealthTechUS· 2017
Prexton Therapeutics
Exited 2018
BiotechCH· 2017
to
Vivet Therapeutics
Vivet Therapeutics
Active
BiotechFR· 2017
Xeltis
Xeltis
Active
MedTechNL· 2017
CorWave
CorWave
Active
MedTechFR· 2016

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track AELIX Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on AELIX Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyers and MOIC on realized deals (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue